Rash or remission? new study aims to decode drug side effect in rare skin cancers
NCT ID NCT07003100
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tracks 100 adults with mycosis fungoides or Sézary syndrome who are starting mogamulizumab, a standard treatment. The drug often causes a rash that can look like the cancer itself. Researchers want to help doctors tell the difference so they don't stop a working drug too soon. Participants will have skin biopsies and blood tests to study the rash.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mogamulizumab
What this could lead to
If successful, this study could help doctors accurately identify mogamulizumab-associated rash, preventing unnecessary early stopping of a working treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. The rash may still be hard to distinguish from disease progression in some cases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Emory University Hospital/Winship Cancer Institute
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fred Hutchinson Cancer Center
NOT_YET_RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johns Hopkins University/Sidney Kimmel Cancer Center
NOT_YET_RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
M D Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Moffitt Cancer Center
NOT_YET_RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Siteman Cancer Center at Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Stanford Cancer Institute Palo Alto
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Thomas Jefferson University Hospital
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact